According to a study published Tuesday, many children are staying much longer in hospitals than they really need to.

FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical ...

Be it peanuts or other triggers, many families live with the day-to-day risk that their child might experience a sudden and ...

Aquestive Therapeutics' Anaphylm offers a unique, non-injectable epinephrine solution for anaphylaxis. Read why AQST stock is ...

A Vineyard woman whose husband died after being stung by a wasp during a golf charity event less than two years ago gave powerful testimony in front of state lawmakers this week, advocating for more ...

Epinephrine (also called adrenaline) and norepinephrine (also called noradrenaline) have a lot in common. Both are hormones that travel through your body, affecting many tissues and organs.

The Food and Drug Administration on Tuesday did not approve Neffy, an epinephrine nasal spray from drugmaker ARS Pharmaceuticals, keeping the first needle-free option for Americans to treat severe ...

Sept. 6, 2024 – People at risk of serious allergic reactions – whether from food, medication or insect bites – could have a needle-free version of epinephrine in their pockets as soon as ...

The hormone epinephrine is the go-to therapy for anaphylaxis, a potentially life-threatening reaction that can happen after exposure to a food, a drug or insect venom for those who are allergic.

44% of children with anaphylaxis received epinephrine before visiting the ED. There was no difference in admission to hospital wards. Children who used epinephrine were less likely to receive ...

The Food and Drug Administration approved the first needle-free alternative to the EpiPen on Friday, a single-use epinephrine nasal spray for the emergency treatment of allergic reactions ...

FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Aquestive Thera ...